New combo therapy before surgery shows promise for esophageal cancer
NCT ID NCT03784326
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study is testing whether adding two immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can help control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery. The main goal is to see if the cancer disappears completely after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat GI cancers
- New drug cocktail aims to fight Hard-to-Treat stomach cancers
- Experimental combo targets Hard-to-Treat esophageal cancer
- Heart monitor reveals hidden damage from cancer radiation
- New study tracks physical decline during cancer treatment
- New drug cocktail targets Hard-to-Treat stomach cancer